6Informed Consent: Risks, Benefits and Alternatives

CDisclosing the surgical and nerve-related risks

Post-activation facial nerve stimulation (a non-injurious side effect, not palsy) occurs in roughly 2.9-5.3% of recipients, rising to as high as 14.9% in otosclerosis; about 46% of affected patients are managed by reprogramming alone. True intraoperative facial nerve injury causing post-operative paralysis is rare at 0.67-1.2%; iatrogenic nerve exposure happens in ~46.6% of cases but produces palsy in only 2.1% of those exposed, falling to 0.72% when the nerve sheath stays intact. Taste disturbance from chorda tympani handling affects ~45% of recipients (taste change in 86% when the chorda is divided), but ~81% recover completely, on average by 20 weeks. Wound and flap complications occur in 0.06-10% of cases (seroma and haematoma most common), and flap necrosis can present up to 5 years post-implant, occasionally exposing the device and requiring revision.[2018][2007][2016][2001][2006]

CDevice, vestibular and CSF/meningitis risks

Modern device survival is high: 97.0% at 5 years, 95.8% at 10 years and 94.9% at 15 years (overall failure ~2.8%); devices implanted after 2013 show no reported failures within 5 years, but candidates must accept the small lifetime chance of re-implantation. Vestibular dysfunction is the commonest complication: caloric testing is abnormal in ~49% at 14 months, yet 74% of patients report no dizziness handicap, so consent should distinguish measurable damage from felt disability. CSF gusher occurs in ~1% of procedures (more with incomplete partition or an enlarged cochlear aperture) and is usually controlled with brief observation and soft-tissue packing; the unsealed CSF-electrode pathway behind the recalled Silastic positioner illustrates why a sealed cochleostomy matters. Post-implant meningitis affects ~0.7% of recipients (reported 1 day to 72 months out), with recipients historically carrying a 138.2-fold elevated pneumococcal meningitis incidence; pneumococcal vaccination at least 2 weeks pre-surgery is a non-negotiable part of consent.[2009][2021][2025][2013][2003][2003]

CTinnitus, residual hearing and the benefit ledger

Pre-existing tinnitus tends to improve: about 58% reduction in loudness and 44% in handicap at 24 months, and only ~3.6% of patients without pre-implant tinnitus develop new-onset tinnitus, so the net tinnitus effect is usually framed as favourable. Even with soft-surgery, residual hearing is at risk: preservation is ~92% acutely (50% complete, 42% partial) but declines to ~69% by 12+ months, and any loss in the implanted ear is irreversible, a hearing aid cannot be reverted to if the implant disappoints. The core benefits to weigh against these risks are durable gains in speech perception and quality of life, reduced social isolation and lower listening effort, realised even by recipients with only modest open-set speech scores. Consent should be calibrated to expectation: ~42% of candidates hold expectations exceeding their 12-month outcomes, and lower pre-operative expectations correlate with higher post-operative quality of life despite equivalent speech gains.[2024][2019][2022][2021][2019]

CPresenting the genuine alternatives

Valid consent requires disclosing non-surgical alternatives: conventional hearing aids (mild-moderate loss), bone conduction devices (conductive loss or single-sided deafness), and middle ear implants (mild-moderate loss with hearing-aid intolerance). Hybrid (electric-acoustic) implants are a distinct option for candidates with preservable low-frequency residual hearing, combining acoustic and electrical stimulation rather than sacrificing the residual hearing entirely. Candidates must understand that choosing the implant means accepting irreversible loss of any usable residual hearing in that ear, and that declining or deferring surgery, continuing with amplification, is itself a legitimate alternative to be weighed.[2018][2019][2006][2024]